Price*, Benedetti*, et.al., The American Journal of Pathology (2022), identified a blood-based protein signature of vascular injury in COVID-19 patients at risk of developing acute respiratory distress syndrome (ARDS), which was associated with lung tissue vascular injury markers. The signature was also predictive of patient survival in an ARDS patient cohort, and of functional outcome in a post-ICU recovery cohort.
Buyukozkan*, Alvarez-Mulett* , et.al., iScience (2022), sought to define the metabolomic and proteomic signatures of COVID-19, and to explore interactions between metabolites and proteins that can serve as a roadmap for future mechanistic studies. The study furthermore proposed a novel clinical composite outcome score that could be used in clinical prediction models for COVID-19.
Batra*, Whalen*, et.al., PLOS Pathogens (2022), describes a first report on the molecular comparison between two ARDS etiologies – COVID-19 and bacterial sepsis. This study is a step toward solving two pertinent clinical challenges associated with ARDS: the identification of novel therapeutic options, and the delineation of heterogeneous pathophysiological manifestations within ARDS groups .
Batra*, Uni*, et.al., Molecular Medicine (2023), describes a first urine-based multi-omic analysis of COVID-19 ARDS compared to bacterial sepsis-induced ARDS. This analysis shows molecular similarities and differences between the two ARDS groups. The most striking finding was a proteomics-based mortality signature specifically for COVID-19 ARDS, which will require further investigation as a potential early biomarker for mortality.